latest news releases from the newsroom
MacroMarkets to Launch MacroShares $100 Oil On July 1
MADISON, N.J., June 30, 2008 (PRIME NEWSWIRE) -- MacroMarkets LLC is pleased to announce that it will launch its second MacroShares products, MacroShares $100 Oil Up (AMEX:OUY) and MacroShares Oil Down (AMEX:DOY) tomorrow when it rings the bell at the American Stock Exchange to open trading.
Franklin Bank, S.S.B. Appoints Interim Chief Executive Officer and Franklin Bank Corp. Announces Extension from Nasdaq and AMEX
HOUSTON, June 30, 2008 (PRIME NEWSWIRE) -- Franklin Bank Corp. (Nasdaq:FBTX) (AMEX:FBK-P.LF) ("Franklin") announced today that Andy Black, the President and Chief Operating Officer of Franklin's subsidiary, Franklin Bank, S.S.B. (the "Bank"), has been appointed to serve as interim Chief Executive Officer of the Bank. Mr. Black, who has been with the Bank since December of 2005, is a veteran commercial and community banker with over 20 years of experience at prominent financial institutions in the Texas marketplace. As a result of Mr. Black's appointment, the executive committee of the Bank that recently has been overseeing the Bank's day to day business activities has been disbanded.
Taro Pharmaceutical Industries Ltd.
Taro Board of Directors to Evaluate Unsolicited Tender Offer From Sun Pharmaceutical Industries Ltd.
HAWTHORNE, N.Y., June 30, 2008 (PRIME NEWSWIRE) -- Taro Pharmaceutical Industries Ltd. ("Taro" or the "Company") (Pink Sheets:TAROF) said today that it would have no formal comment on the unsolicited tender offer commenced today by a subsidiary of Sun Pharmaceutical Industries Ltd. ("Sun"), for all shares of Taro common stock at a price of $7.75 per share until Taro's Board of Directors has an opportunity to review and evaluate the full details of the offer.
OceanFirst Financial Corp.
OceanFirst Financial Corp. Schedules Earnings Conference Call
TOMS RIVER, N.J., June 30, 2008 (PRIME NEWSWIRE) -- OceanFirst Financial Corp. (Nasdaq:OCFC), the holding company for OceanFirst Bank, today announced that it will issue its earnings release for the quarter ended June 30, 2008 at approximately 8:00 a.m. Eastern Time on Thursday, July 24, 2008. Management will then conduct a conference call at 10:30 a.m. Eastern Time, on Thursday, July 24, 2008, to discuss highlights of the Company's second quarter operating performance.
Alico, Inc. Appoints Dan L. Gunter as Chief Executive Officer
LABELLE, Fla., June 30, 2008 (PRIME NEWSWIRE) -- Alico, Inc. (Nasdaq:ALCO), a land management company, announced that Dan L. Gunter, President and Chief Operating Officer, was named Chief Executive Officer of the Company effective July 1, 2008. Mr. Gunter will succeed John R. Alexander who held the CEO position since February 2005, following Mr. Alexander's retirement. Mr. Alexander will continue in his role of Chairman of the Board.
Ivivi Technologies, Inc.
Ivivi Technologies Reports Fiscal 2008 Financial Results and Comments On FDA Matter
MONTVALE, N.J., June 30, 2008 (PRIME NEWSWIRE) -- Ivivi Technologies, Inc. (Nasdaq:IVVI), a leader in non-invasive, electroceutical(r) therapy systems designed to target and enhance the body's anti-inflammatory response, today announced financial results for its fiscal fourth quarter and year ended March 31, 2008.
Ivivi Technologies, Inc.
'No-Option' Cardiac Patients Have Significantly Reduced Angina and Improved Exercise Tolerance With Ivivi Technologies tPEMF Therapy in Cleveland Clinic Florida Trial; Future Studies Planned
MONTVALE, N.J., June 30, 2008 (PRIME NEWSWIRE) -- Ivivi Technologies, Inc. (Nasdaq:IVVI), a leader in non-invasive, electroceutical(r) therapy systems designed to enhance the body's natural anti-inflammatory response, today announced that the Cleveland Clinic, in Westin, Florida, has released the results of its double-blind, randomized, placebo-controlled and prospective clinical trial (EFFECT trial) utilizing the Company's proprietary targeted pulsed electromagnetic field (tPEMF(tm)) technology. In the study of 30 patients with cardiomyopathies and no other treatment options, the patients in the active treatment arm demonstrated significant reductions in anginal pain and frequency, with an accompanying reduction in nitroglycerine use. These results began emerging at one month after commencement of treatment, with increasing significance at three and five month intervals. The changes in clinical outcomes were consistent with those seen in angina patients who can and do undergo successful angioplasty.